Arch Venture Funds Disclose Stake in Boundless Bio

TL;DR

**ARCH Venture Funds now hold significant stake in Boundless Bio. Watch this space.**

AI Summary

ARCH Venture Fund IX, L.P. and related entities filed a Schedule 13D on October 29, 2024, regarding their beneficial ownership of Boundless Bio, Inc. The filing indicates a change in ownership or control, with ARCH Venture Fund IX, L.P. and other ARCH Venture entities listed as group members. The filing does not specify a dollar amount or a specific date of change beyond the filing date.

Why It Matters

This filing signals a significant ownership change or increased influence by ARCH Venture entities in Boundless Bio, potentially impacting the company's strategic direction or future M&A activity.

Risk Assessment

Risk Level: medium — Schedule 13D filings often precede significant corporate actions or shifts in control, which can introduce volatility.

Key Players & Entities

• ARCH Venture Fund IX, L.P. (company) — Filing entity
• Boundless Bio, Inc. (company) — Subject company
• ARCH Venture Fund X OVERAGE, L.P. (company) — Group member
• ARCH Venture Partners IX, L.P. (company) — Group member
• Clinton Bybee (person) — Group member
• Keith Crandell (person) — Group member
• Kristina Burow (person) — Group member
• Robert Nelsen (person) — Group member
• Steven Gillis (person) — Group member

FAQ

Key Financial Figures

• $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securiti
• $13.65 — ck of the Issuer at a purchase price of $13.65 per share. The number of shares reflect
• $16.00 — es of Common Stock at purchase price of $16.00 from the underwriters in the Issuer&rsq

Filing Documents

• arch-sch13d_18895.htm (SC 13D) — 471KB
• 0001072613-24-000789.txt ( ) — 473KB

Security

Item 1. Security and Issuer . This statement relates to the Common Stock, $0.0001 par value per share (the “Common Stock”), of Boundless Bio, Inc. (the “Issuer”) having its principal executive office at 9880 Campus Point Drive, Suite 120, San Diego, CA 9212.

IDENTITY

Item 2. IDENTITY AND BACKGROUND . (a) ARCH Venture Fund IX, L.P. (“AVF IX”); ARCH Venture Partners IX, L.P. (“AVP IX GP”); ARCH Venture Partners IX, LLC (“AVP IX LLC”); ARCH Venture Fund IX Overage, L.P. (“AVF IX Overage”); ARCH Venture Partners IX Overage, L.P. (“AVP IX Overage GP”); ARCH Venture Fund X Overage, L.P. (“AVF X Overage”); ARCH Venture Partners X Overage, L.P. (“AVP X Overage GP”); ARCH Venture Partners X, LLC (“AVP X LLC” and collectively, the “Reporting Entities” and individually, each a “Reporting Entity”); and Keith Crandell (“Crandell”), Robert Nelsen (“Nelsen”) and Clinton Bybee (“Bybee”) (collectively, the “Managing Directors” and individually, each a “Managing Director”), and Steven Gillis (“Gillis”) and Kristina Burow (“Burow”), along with Nelsen and Crandell, collectively the “Investment Committee”; individually “Committee members”. The Reporting Entities, Managing Directors and the Investment Committee members collectively are referred to as the “Reporting Persons”. (b) The business address of each of the Reporting Persons is 8755 West Higgins Road, Suite 1025, Chicago, IL, 60631. (c) The principal business of AVP IX GP is to act as the general partner of AVF IX, the principal business of AVP IX Overage GP is to act as the general partner of AVF IX Overage, and the principal business of AVP X Overage GP is to act as the general partner of AVF X Overage. The principal business of AVP IX LLC is to act as the general partner of AVP IX GP and AVF IX Overage GP, and the principal business of AVP X LLC is to act as the general partner of AVF X Overage GP. The principal business of each of the Managing Directors is to act as managing directors of AVP IX LLC, and as managing directors or investment committee

Material

Item 7. Material to be Filed as Exhibits . Exhibit 1- Agreement of Joint Filing Exhibit 2- Agreement of Joint Filing Exhibit 3- Amended and Restated Investors’ Rights Agreement, dated April 5, 2023, as amended, by and among the Issuer and certain of its stockholders (incorporated by reference to Exhibit 4.2 to the Issuer’s Registration Statement on Form S-1 (File No. 333-277696), as filed with the Securities and Exchange Commission on March 6, 2024). Exhibit 4- Form of Lock-Up Agreement (incorporated by reference to Annex II to the Form of Underwriting Agreement filed as Exhibit 1.1 to the Issuer’s amended Registration Statement on Form S-1/A (File No. 333-277696) as filed with the Securities and Exchange Commission on March 21, 2024). CUSIP No. 10170A100 13D Page 20 of 25 Pages Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date:October 29, 2024 ARCH VENTURE FUND IX, L.P. By: ARCH Venture Partners IX, L.P. its General Partner By: ARCH Venture Partners IX, LLC its General Partner By: * Keith Crandell Managing Director ARCH VENTURE PARTNERS IX, L.P. By: ARCH Venture Partners IX, LLC its General Partner By: * Keith Crandell Managing Director ARCH VENTURE PARTNERS IX, LLC By: * Keith Crandell Managing Director ARCH VENTURE FUND IX OVERAGE, L.P. By: ARCH Venture Partners IX Overage, L.P. its General Partner . By:ARCH Venture Partners IX, LLC its General Partner By: * Keith Crandell Managing Director ARCH VENTURE PARTNERS IX OVERAGE, L.P. By: ARCH Venture Partners IX, LLC its General Partner By: * Keith Crandell Managing Director CUSIP No. 10170A100 13D Page 21 of 25 Pages ARCH VENTURE PARTNERS IX, LLC By: * Keith Crandell Managing Director * Keith Crandell * Clinton Bybee * Robert Nelsen * By: /s/ Mark McDonnell Mark McDonnell Attorney-in-Fact * T

View Full Filing

View this SC 13D filing on SEC EDGAR